Bafna Pharmaceuticals Limited (BAFNAPH.NS)
INR 74.87
(3.27%)
INR 74.87
(3.27%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 296.41 Million INR | 33.4% |
| 2022 | 222.19 Million INR | 9.56% |
| 2021 | 202.8 Million INR | 31.32% |
| 2020 | 154.43 Million INR | 35.33% |
| 2019 | 114.11 Million INR | 22.94% |
| 2018 | 92.82 Million INR | -13.04% |
| 2017 | 106.74 Million INR | -36.24% |
| 2016 | 167.39 Million INR | 2.2% |
| 2015 | 163.79 Million INR | 1.59% |
| 2014 | 161.22 Million INR | -41.16% |
| 2013 | 274.01 Million INR | 23.36% |
| 2012 | 222.12 Million INR | -7.13% |
| 2011 | 239.18 Million INR | 62.19% |
| 2010 | 147.47 Million INR | 57.93% |
| 2009 | 93.38 Million INR | 100.53% |
| 2008 | 46.56 Million INR | -13.3% |
| 2007 | 53.71 Million INR | -18.14% |
| 2006 | 65.61 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 293.62 Million INR | 0.0% |
| 2023 FY | 296.41 Million INR | 33.4% |
| 2023 Q4 | 296.41 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 222.19 Million INR | 0.0% |
| 2022 FY | 222.19 Million INR | 9.56% |
| 2022 Q2 | 215.78 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 187.55 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 202.8 Million INR | 0.0% |
| 2021 FY | 202.8 Million INR | 31.32% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 137.41 Million INR | 0.0% |
| 2020 FY | 154.43 Million INR | 35.33% |
| 2020 Q4 | 154.43 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 114.11 Million INR | 22.94% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 111.83 Million INR | 0.0% |
| 2019 Q4 | 114.11 Million INR | 0.0% |
| 2018 FY | 92.82 Million INR | -13.04% |
| 2018 Q4 | 92.82 Million INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 106.74 Million INR | -36.24% |
| 2016 FY | 167.39 Million INR | 2.2% |
| 2015 FY | 163.79 Million INR | 1.59% |
| 2014 FY | 161.22 Million INR | -41.16% |
| 2013 FY | 274.01 Million INR | 23.36% |
| 2012 FY | 222.12 Million INR | -7.13% |
| 2012 Q2 | 351.54 Million INR | 0.0% |
| 2012 Q4 | 222.12 Million INR | 0.0% |
| 2011 FY | 239.18 Million INR | 62.19% |
| 2010 FY | 147.47 Million INR | 57.93% |
| 2009 FY | 93.38 Million INR | 100.53% |
| 2008 FY | 46.56 Million INR | -13.3% |
| 2007 FY | 53.71 Million INR | -18.14% |
| 2006 FY | 65.61 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Hester Biosciences Limited | 755.81 Million INR | 60.781% |
| RPG Life Sciences Limited | 1.01 Billion INR | 70.652% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 87.179% |
| Ipca Laboratories Limited | 24.71 Billion INR | 98.801% |
| Aarti Drugs Limited | 4.85 Billion INR | 93.899% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 95.389% |
| Albert David Limited | 436.12 Million INR | 32.033% |
| Alembic Limited | 113.4 Million INR | -161.392% |
| Alkem Laboratories Limited | 26.61 Billion INR | 98.886% |
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 98.196% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 79.421% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -1062.56% |
| Brooks Laboratories Limited | 96.1 Million INR | -208.422% |
| Eris Lifesciences Limited | 1.89 Billion INR | 84.319% |
| FDC Limited | 3.88 Billion INR | 92.378% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 95.553% |
| Gufic Biosciences Limited | 2 Billion INR | 85.215% |
| Hikal Limited | 3.03 Billion INR | 90.24% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -183.445% |
| Ind-Swift Limited | 640.91 Million INR | 53.751% |
| Innova Captab Limited | 1.44 Billion INR | 79.418% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 93.023% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -97.652% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 97.701% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -643.275% |
| Laurus Labs Limited | 18.45 Billion INR | 98.394% |
| Lincoln Pharmaceuticals Limited | 771.68 Million INR | 61.588% |
| Lupin Limited | 49.53 Billion INR | 99.402% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 76.026% |
| Medico Remedies Limited | 163.37 Million INR | -81.437% |
| Morepen Laboratories Limited | 2.48 Billion INR | 88.076% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 95.82% |
| Orchid Pharma Limited | 2.64 Billion INR | 88.782% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 72.833% |
| Sigachi Industries Limited | 707.2 Million INR | 58.086% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 91.759% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.7% |
| Themis Medicare Limited | 705.74 Million INR | 57.999% |
| Unichem Laboratories Limited | 7.04 Billion INR | 95.794% |
| Vaishali Pharma Limited | 3.79 Million INR | -7706.637% |
| Venus Remedies Limited | 1.21 Billion INR | 75.642% |
| Wanbury Limited | 360.23 Million INR | 17.715% |
| Windlas Biotech Limited | 621.89 Million INR | 52.336% |
| ZIM Laboratories Limited | 812.62 Million INR | 63.524% |
| Sakar Healthcare Limited | 277.32 Million INR | -6.885% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.698% |
| Divi's Laboratories Limited | 31.84 Billion INR | 99.069% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 86.992% |
| Mankind Pharma Limited | 15.53 Billion INR | 98.092% |
| Sequent Scientific Limited | 3.46 Billion INR | 91.439% |
| Neuland Laboratories Limited | 3.5 Billion INR | 91.541% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 94.101% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 98.82% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 99.139% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -2.55% |
| Wockhardt Limited | 6.4 Billion INR | 95.368% |
| Bal Pharma Limited | 878.11 Million INR | 66.244% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 99.534% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 74.975% |
| Par Drugs and Chemicals Limited | 41.77 Million INR | -609.643% |
| Caplin Point Laboratories Limited | 3.63 Billion INR | 91.835% |
| Shilpa Medicare Limited | 3.44 Billion INR | 91.406% |
| Valiant Laboratories Limited | 100.15 Million INR | -195.962% |
| Ajanta Pharma Limited | 8.28 Billion INR | 96.422% |
| Aarey Drugs & Pharmaceuticals Limited | 346.75 Million INR | 14.517% |
| Granules India Limited | 13 Billion INR | 97.721% |
| Medicamen Biotech Limited | 593.75 Million INR | 50.077% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -40.606% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 98.699% |
| NATCO Pharma Limited | 7 Billion INR | 95.768% |
| Suven Life Sciences Limited | 7.08 Million INR | -4083.74% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -202.578% |
| Strides Pharma Science Limited | 11.26 Billion INR | 97.368% |
| Indoco Remedies Limited | 3.53 Billion INR | 91.604% |
| Alpa Laboratories Limited | 136.65 Million INR | -116.913% |
| Lasa Supergenerics Limited | 190.43 Million INR | -55.654% |
| Sun Pharma Advanced Research Company Limited | 14.79 Million INR | -1903.908% |